ImmunityBio, Inc. — Director's Dealing 2025

Dec 16, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2025-12-12

Reporting Person: Wendel Bruce (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-12	Stock Option (right to buy)	$2.36	A	146020	Acquired	2035-12-12	Common Stock (146020)	Direct

Footnotes

F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2025 Equity Incentive Plan) through each applicable vesting date, 48,673 of the shares subject to the award will vest on December 12, 2026, 48,673 of the shares subject to the award will vest on December 12, 2027 and 48,674 of the shares subject to the award will vest on December 12, 2028, such that the award will be fully vested on December 12, 2028; provided that, notwithstanding the foregoing, any unvested shares subject to the award will fully vest immediately prior to a Change in Control (as defined in the 2025 Equity Incentive Plan), subject to the reporting person continuing to be a Service Provider through the date of such Change in Control.